Julie Bergeron

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget et al. · New England Journal of Medicine · 2017 · 2.1K citations · Full text

Medicine, Hematology, Oncology +16

A common haplotype in the complement regulatory gene factor H ( <i>HF1/CFH</i> ) predisposes individuals to age-related macular degeneration

Gregory S. Hageman, Don H. Anderson, Lincoln V. Johnson et al. · Proceedings of the National Academy of Sciences · 2005 · 2K citations · Full text

Medicine, Genetics, Molecular Genetics +17

Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration

Bert Gold, Joanna E. Merriam, Jana Zernant et al. · Nature Genetics · 2006 · 1.1K citations

Medicine, Genetics, Ophthalmology +15

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

Andrew H. Wei, Pau Montesinos, Vladimir Ivanov et al. · Blood · 2020 · 756 citations · Full text

Medicine, Oncology, Pharmacology +9

Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33

Bert Gold, Tomas Kirchhoff, James A. Lautenberger et al. · Proceedings of the National Academy of Sciences · 2008 · 299 citations · Full text

Life Sciences, Genetics, Molecular Genetics +14